Trial Profile

A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2024 Results of post-hoc anaylsis involving study of mepolizumab in patients with SA-EP, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
24 May 2023 Primary endpoint has been met (Number of clinically significant exacerbations of asthma at week 52) , according to Results presented at the 119th International Conference of the American Thoracic Society
24 May 2023 Results reporting safety and efficacy outcomes data at week 52 presented at the 119th International Conference of the American Thoracic Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com